PDCD1 and neoplasm: Wang et al. (17) described a HER3-PI3K-mammalian target of rapamycin signaling axis driving the immune-suppressive tumor microenvironment as well as a therapeutic vulnerability to dual-HER3/programmed cell death 1 protein blockade.